publication date: May. 24, 2019
Issue 21 - May. 24, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Trials & Tribulations

    Why I choose to play a dual role in TMIST

    As a physician-scientist, I have spent my career advancing research in women’s health. I was a part of the planning effort to design and launch TMIST—the Tomosynthesis Mammographic Imaging Screening Trial.

  • Dana-Farber wins legal dispute over PD-1/PD-L1 patents; BMS set to lose exclusive license

    So, you’ve finished your copy of the Mueller Report and you long for another great read from the same publisher—the U.S. government.

  • Review

    Chernobyl, the HBO miniseries: Fact and fiction (Part II)

    Last week, I discussed events resulting in the Chernobyl NPF accident, including unique aspects of the reactor-design which contributed to the accident, and which resulted in release of radiation to the environment. I also discussed the initial Soviet response. Next, I focus on the immediate medical consequences and the response of Soviet government to medical interventions.

  • In Brief

    • Mullighan named deputy director of St. Jude
    • Dimopoulos and Mateos to receive achievement awards from IMF
    • Singh named sub-PI Heartland Cancer Research NCORP Executive Committee
    • Douglas Lowy receives NYU honorary degree
  • Funding Opportunities

    Astellas Oncology calls for entries to C3 Prize to award $200,000

    Astellas Pharma Inc. is calling for entries for the fourth annual Astellas Oncology C3 Prize (Changing Cancer Care), a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones.

  • TCCL Logo

  • Clinical Roundup

    • UPenn study shows adding bevacizumab improves OS in NSCLC
    • NRG Oncology phase III study results: partial breast irradiation is effective
    • First states to expand Medicaid saw larger screening rate increases
  • Drugs & Targets

    • Oncopeptides to submit NDA for melflufen in multiple myeloma

Copyright (c) 2020 The Cancer Letter Inc.